Comparison of inflammatory and nutritional markers obtained at the time of diagnosis in patients diagnosed with renal cell carcinoma

肾细胞癌患者确诊时炎症和营养标志物的比较

阅读:2

Abstract

This study aimed to compare the prognostic significance of inflammatory and nutritional parameters, calculated based on hemogram and biochemical values at the time of diagnosis, in patients diagnosed with renal cell carcinoma (RCC). A total of 120 patients diagnosed with RCC and receiving diagnosis and/or treatment at our center were included in the study. Among the inflammatory and nutritional parameters, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), modified Glasgow prognostic score (mGPS), and Memorial Sloan Kettering prognostic score (MPS) were calculated and analyzed. The most common pathological subtype was the clear cell variant (69.2%). 25.8% of the patients were at the metastatic stage. Univariate Cox regression analysis revealed that tumor size, tumor grade, sex, stage, presence of metastasis, number of metastases, IVC involvement, history of radiotherapy (RT), hemoglobin, NLR, PLR, PNI, albumin, C-reactive protein (CRP), MPS, and mGPS had a significant impact on survival. Furthermore, stage, number of metastases, and PNI were identified as independent prognostic factors for survival. When clinical parameters were excluded from the analysis, NLR, LDH, and mGPS emerged as independent prognostic factors for survival.As demonstrated by the results of the multivariate analysis, stage, number of metastases, and PNI were found to be more influential independent prognostic factors. This study suggests that nutritional parameters have greater prognostic value than inflammatory markers in RCC, and that a simple nutritional scoring system performed at the time of diagnosis may provide improved prognostic accuracy. Additionally, our findings indicate that the MPS, which was evaluated for the first time in RCC in this study, also has prognostic significance, and it may potentially become an independent prognostic marker in future studies with larger patient populations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。